[{"id":"c645658f-9888-4b76-a6ed-05ba5b167c94","acronym":"","url":"https://clinicaltrials.gov/study/NCT05329298","created_at":"2022-04-15T12:53:38.398Z","updated_at":"2024-07-02T16:36:12.343Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05329298","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-361175"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-04-15"}]